View Older Stories View More Recent Stories

Jul 31, 2024 07:00AM Kymera Therapeutics to Report Second Quarter 2024 Financial Results on August 7
Jul 9, 2024 07:00AM Kymera Therapeutics to Present in Fireside Chat at the UBS Virtual Targeted Protein Degradation Day
Jul 8, 2024 04:05PM Kymera Therapeutics (KYMR) Announces Expansion of KT-474 HS and AD Phase 2 Studies
Jul 8, 2024 04:05PM Kymera Announces Expansion of KT-474 (SAR444656) HS and AD Phase 2 Studies Following Interim Review of Safety and Efficacy
Jun 20, 2024 08:45AM Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033
Jun 14, 2024 07:01AM Kymera Therapeutics (KYMR) Presents New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting
Jun 14, 2024 07:00AM Kymera Therapeutics Presents New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting
Jun 1, 2024 08:00AM Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting
May 29, 2024 07:00AM Kymera Therapeutics to Participate in Upcoming June Investor Conferences
May 29, 2024 07:00AM Kymera Therapeutics to Participate in Upcoming June Investor Conferences
May 23, 2024 05:00PM Kymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting
May 22, 2024 11:20AM Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the ATS Annual Meeting
May 14, 2024 10:00AM Kymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting
May 8, 2024 07:00AM Kymera Therapeutics to Participate in Upcoming May Investor Conferences
May 2, 2024 07:00AM Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business Update
Apr 25, 2024 07:00AM Kymera Therapeutics to Report First Quarter 2024 Financial Results on May 2
Apr 8, 2024 07:25AM Kymera Therapeutics (KYMR) Announces Scientific Presentations at the American Association for Cancer Research
Apr 8, 2024 07:00AM Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting
Mar 8, 2024 10:00AM Kymera Therapeutics (KYMR) Presents Preclinical Data for STAT6 and TYK2
Mar 8, 2024 10:00AM Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of Dermatology Annual Meeting
Feb 28, 2024 07:00AM Kymera Therapeutics to Participate in Upcoming March Investor Conferences
Feb 22, 2024 07:00AM Kymera Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
Feb 15, 2024 07:00AM Kymera Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 22
Jan 31, 2024 07:00AM Kymera Therapeutics to Present in Fireside Chat at the Guggenheim Healthcare Conference
Jan 9, 2024 09:17AM Kymera Therapeutics Outlines Key 2024 Objectives and Strategy to Progress Leading Portfolio of Immunology and Oncology Programs
Jan 4, 2024 07:00AM R&D Day Highlights Kymera’s Immunology Strategy and Emerging Pipeline of Novel, First-in-Class Oral Degraders Addressing Multiple Highly Prevalent Immuno-inflammatory Diseases
Jan 4, 2024 07:00AM R&D Day Highlights Kymera’s Immunology Strategy and Emerging Pipeline of Novel, First-in-Class Oral Degraders Addressing Multiple Highly Prevalent Immuno-inflammatory Diseases
Jan 2, 2024 07:00AM Kymera Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024
Dec 13, 2023 07:00AM Kymera Therapeutics to Host Virtual Immunology R&D Day on January 4
Dec 13, 2023 07:00AM Kymera Therapeutics to Host Virtual Immunology R&D Day on January 4
Dec 11, 2023 03:39AM Kymera Therapeutics (KYMR) Presents Interim Results from STAT3 Degrader Phase 1 Trial
Dec 10, 2023 09:00PM Kymera Therapeutics Presents Interim Results from STAT3 Degrader Phase 1 Clinical Trial at American Society of Hematology Annual Meeting
Dec 7, 2023 07:00AM Kymera Therapeutics Announces First Patient Dosed in Phase 2 Atopic Dermatitis Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating a $15 Million Payment
Nov 13, 2023 11:04AM Kymera Therapeutics (KYMR) Announces Publication of Phase 1 Trial Results for KT-474
Nov 13, 2023 11:00AM Kymera Therapeutics Announces Publication of Phase 1 Trial Results for KT-474 (SAR444656), a First-in-Class IRAK4 Degrader, in Nature Medicine
Nov 2, 2023 09:00AM Kymera Therapeutics to Present New Clinical Data from the Phase 1 Trial of STAT3 Degrader KT-333 at the ASH Annual Meeting
Nov 2, 2023 07:00AM Kymera Therapeutics Announces Third Quarter 2023 Financial Results and Provides a Business Update
Nov 1, 2023 07:00AM Kymera Therapeutics to Participate in Upcoming November Investor Conferences
Oct 27, 2023 07:00AM Kymera Therapeutics Announces First Patient Dosed in Phase 2 Hidradenitis Suppurativa Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating $40 Million Pay
Oct 26, 2023 07:00AM Kymera Therapeutics to Report Third Quarter 2023 Financial Results on November 2
Oct 16, 2023 07:01AM Kymera Therapeutics (KYMR) Presents Preclinical Data Demonstrating Activity of MDM2 Degraders in Acute Myeloid Leukemia and Merkel Cell Carcinoma
Oct 16, 2023 07:00AM Kymera Therapeutics Presents Preclinical Data Demonstrating Activity of MDM2 Degraders in Acute Myeloid Leukemia and Merkel Cell Carcinoma
Sep 18, 2023 07:01AM Kymera Therapeutics (KYMR) Receives U.S. FDA Fast Track Designation for KT-333 for CTCL and R/R PTCL
Sep 18, 2023 07:00AM Kymera Therapeutics Receives U.S. FDA Fast Track Designation for KT-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Relapsed/Refractory Cutaneous T-Cell Lymphoma and Relapse
Aug 28, 2023 07:00AM Kymera Therapeutics to Participate in Upcoming September Investor Conferences
Aug 3, 2023 07:00AM Kymera Therapeutics Announces Second Quarter 2023 Financial Results and Provides a Business Update
Jul 27, 2023 07:00AM Kymera Therapeutics to Report Second Quarter 2023 Financial Results on August 3
Jun 22, 2023 08:30AM Kymera Therapeutics Receives FDA Orphan Drug Designation for KT-253, a Novel, Highly Potent and Selective MDM2 Degrader for the Treatment of Acute Myeloid Leukemia
Jun 14, 2023 04:46AM Kymera Therapeutics' (KYMR) STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413 Demonstrate Desired Target Knockdown and Safety with Continued Dose Escalation in Ongoing Phase I Trials
Jun 14, 2023 02:30AM Kymera Therapeutics’ STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413 Demonstrate Desired Target Knockdown and Safety with Continued Dose Escalation in Ongoing Phase I Clinical Trials
View More Recent Stories View Older Stories